Why this ASX biotech stock could rise a massive 40%

Bell Potter sees big returns on the cards for investors from this speculative stock.

| More on:
A couple stares at the tv in shock, one holding the remote up ready to press.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're on the lookout for big returns, then you may want to check out Clarity Pharmaceuticals Ltd (ASX: CU6).

That's because analysts at Bell Potter believe that the ASX biotech stock could generate big returns for investors with a high tolerance for risk over the next 12 months.

What is the broker saying about this ASX biotech stock?

According to a note, the broker was pleased with its recent announcement relating to the SECuRE trial, which is investigating the therapeutic qualities of 67Cu-SAR-bisPSMA in metastatic castrate resistant prostate cancer (mCRPC).

That announcement revealed that the preliminary data showed that despite having high levels of prostate-specific antigen (PSA) and having received multiple treatments, 60% of participants across all cohorts showed reductions in PSA levels of greater than 35% from a single therapy cycle of 67Cu-SAR-bisPSMA.

In addition, no dose limiting toxicities (DLTs) have been reported in cohort 3 to date, with most adverse events being mild or moderate and comfortably below levels that would cause investigators genuine concern.

In response to the trial data, Bell Potter said:

All cohorts have shown encouraging levels of reduction in PSA from a single dose of therapy. The announcement does not include progression free survival data, however, case studies from the EAP group which have now received multiple doses are highly encouraging, both from a safety and efficacy standpoint. Each of these patients remains alive and apparently with no disease progression, many months after commencing treatment. In one case PSA has reduced to undetectable levels with PET imaging showing a near complete response.

In summary, very pleasing data from SECuRE, strongly supportive of further investigation.

Major upside ahead

Bell Potter has held firm with its speculative buy rating and $3.90 price target on the ASX biotech stock.

Based on its current share price of $2.75, this implies potential upside of 42% for investors over next 12 months.

Though, it is worth remembering that its rating comes with a speculative tag. This means it may only be suitable for investors with a high tolerance for risk.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Guess which ASX 300 healthcare stock is storming higher on Chinese patent news

Here's why this healthcare share is catching the eye on Thursday.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Guess which ASX healthcare stock is rocketing 110% on US product launch

Shareholders of this stock are smiling on Wednesday. Why is it rocketing?

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Own CSL shares? You're receiving a healthy dividend boost today!

The bank accounts of CSL shareholders are about to receive a healthy payment.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Blast off! Mesoblast share price surging 60%

Mesoblast shares are skyrocketing today.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL share price lower despite US FDA boost

The regulator has approved a treatment for sufferers of chronic kidney disease.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »